Pharmacokinetics and Safety of a Fully Human Hepatocyte Growth Factor Antibody, AMG 102, in Cynomolgus Monkeys
Rent the article at a discountRent now
* Final gross prices may vary according to local VAT.Get Access
AMG 102, a fully human monoclonal antibody that binds to hepatocyte growth factor (HGF), is a potential cancer therapeutic agent because of its ability to disrupt HGF/c-Met signaling pathways which have been implicated in most tumor types. To support a phase 1 study, the pharmacokinetic and safety profile of AMG 102 was assessed in cynomolgus monkeys.
Materials and Methods
Serum concentration-time data from single-(IV and SC) and repeated-dose (IV) studies of up to 13 weeks were used for pharmacokinetic analysis. Safety was assessed in a single-dose safety pharmacology study with IV doses of 0 (vehicle), 25, 100, or 300 mg/kg and a 4-week toxicity study with once weekly IV doses of 0 (vehicle), 5, 25, or 100 mg/kg.
AMG 102 exhibited linear pharmacokinetics over a 600-fold dose range (0.5 to 300 mg/kg) with a mean terminal half-life of 5.6 days after IV dosing. Clearance and volume of distribution at steady state were 1.22 ml/h and 198.3 ml, respectively. Estimated bioavailability was 72% for SC administration. Antibody response to AMG 102 was observed in a small percentage of monkeys. No treatment-related cardiovascular, respiratory, or CNS changes were observed. Administration of AMG 102 for 4 weeks was well tolerated at doses up to 100 mg/kg. Potential treatment-related effects were limited to minimal/moderate gastric mucosa hemorrhage in the mid- and high-dose groups.
The nonclinical pharmacokinetic and safety profile of AMG 102 effectively supports clinical investigation.
- Birchmeier, C., Birchmeier, W., Gherardi, E., Woude, G. F. (2003) Met, metastasis, motility and more. Nat. Rev., Mol. Cell Biol. 4: pp. 915-925 CrossRef
- Trusolino, L., Comoglio, P. M. (2002) Scatter-factor and semaphorin receptors: cell signalling for invasive growth. Nat. Rev., Cancer 2: pp. 289-300 CrossRef
- Danilkovitch-Miagkova, A., Zbar, B. (2002) Dysregulation of Met receptor tyrosine kinase activity in invasive tumors. J. Clin. Invest. 109: pp. 863-867 CrossRef
- Maulik, G., Shrikhande, A., Kijima, T., Ma, P. C., Morrison, P. T., Salgia, R. (2002) Role of the hepatocyte growth factor receptor, c-Met, in oncogenesis and potential for therapeutic inhibition. Cytokine Growth Factor Rev. 13: pp. 41-59 CrossRef
- Schmidt, L., Duh, F. M., Chen, F., Kishida, T., Glenn, G., Choyke, P., Scherer, S. W., Zhuang, Z., Lubensky, I., Dean, M., Allikmets, R., Chidambaram, A., Bergerheim, U. R., Feltis, J. T., Casadevall, C., Zamarron, A., Bernues, M., Richard, S., Lips, C. J., Walther, M. M., Tsui, L. C., Geil, L., Orcutt, M. L., Stackhouse, T., Lipan, J., Slife, L., Brauch, H., Decker, J., Niehans, G., Hughson, M. D., Moch, H., Storkel, S., Lerman, M. I., Linehan, W. M., Zbar, B. (1997) Germline and somatic mutations in the tyrosine kinase domain of the MET proto-oncogene in papillary renal carcinomas. Nat. Genet. 16: pp. 68-73 CrossRef
- Ma, P. C., Jagadeeswaran, R., Jagadeesh, S., Tretiakova, M. S., Nallasura, V., Fox, E. A., Hansen, M., Schaefer, E., Naoki, K., Lader, A., Richards, W., Sugarbaker, D., Husain, A. N., Christensen, J. G., Salgia, R. (2005) Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer. Cancer Res. 65: pp. 1479-1488 CrossRef
- Mukohara, T., Civiello, G., Davis, I.J., Taffaro, M.L., Christensen, J., Fisher, D. E., Johnson, B. E., Janne, P. A. (2005) Inhibition of the met receptor in mesothelioma. Clin. Cancer Res. 11: pp. 8122-8130 CrossRef
- Forbs, D., Thiel, S., Stella, M. C., Sturzebecher, A., Schweinitz, A., Steinmetzer, T., Sturzebecher, J., Uhland, K. (2005) In vitro inhibition of matriptase prevents invasive growth of cell lines of prostate and colon carcinoma. Int. J. Oncol. 27: pp. 1061-1070
- Burgess, T., Coxon, A., Meyer, S., Sun, J., Rex, K., Tsuruda, T., Chen, Q., Ho, S. Y., Li, L., Kaufman, S., McDorman, K., Cattley, R. C., Sun, J., Elliott, G., Zhang, K., Feng, X., Jia, X. C., Green, L., Radinsky, R., Kendall, R. (2006) Fully human monoclonal antibodies to hepatocyte growth factor with therapeutic potential against hepatocyte growth factor/c- Met-dependent human tumors. Cancer Res. 66: pp. 1721-1729 CrossRef
- Beal, S. L., Sheiner, and L. B. (1989) NONMEM Users Guide—Part I Users Basic Guide. NONMEM Project Group UCSF, San Francisco, CA
- Boxenbaum, H. G., Riegelman, S., Elashoff, R. M. (1974) Statistical estimations in pharmacokinetics. J. Pharmacokinet. Biopharm. 2: pp. 123-148 CrossRef
- Davies, B., Morris, T. (1993) Physiological parameters in laboratory animals and humans. Pharm. Res. 10: pp. 1093-1095 CrossRef
- Lobo, E. D., Hansen, R. J., Balthasar, J. P. (2004) Antibody pharmacokinetics and pharmacodynamics. J. Pharm. Sci. 93: pp. 2645-2668 CrossRef
- Jiang, W. G., Martin, T. A., Parr, C., Davies, G., Matsumoto, K., Nakamura, T. (2005) Hepatocyte growth factor, its receptor, and their potential value in cancer therapies. Crit. Rev. Oncol./Hematol. 53: pp. 35-69 CrossRef
- Woude, G. F., Jeffers, M., Cortner, J., Cortner, J., Alvord, G., Tsarfaty, I., Resau, J. (1997) , et al. Met-HGF/SF tumorigenesis, invasion and metastatis. Ciba Found Symp. 212: pp. 119-130
- T. Burgess, J. Sun, S. Meyer, J. Sun, G. Elliott, Q. Chen, S.Y. Ho, R. Jacobsen, H. Kim, R. Deshpande, F. Martin, T. Tsuruda, K. Zhang, M. Haniu, A. Coxon, and R. Kendall. Characterization of fully human monoclonal antibodies to human hepatocyte growth factor, presented as a “Late Breaking” Abstract #288 at the AACR Annual Meeting, Washington, DC, 2006.
- Pharmacokinetics and Safety of a Fully Human Hepatocyte Growth Factor Antibody, AMG 102, in Cynomolgus Monkeys
Volume 24, Issue 10 , pp 1910-1918
- Cover Date
- Print ISSN
- Online ISSN
- Springer US
- Additional Links
- anti-HGF antibody
- hepatocyte growth factor
- tyrosine kinase
- Industry Sectors
- Author Affiliations
- 1. Department of Pharmacokinetics and Metabolism, Amgen Inc., Thousand Oaks, California, 91320, USA
- 4. Amgen Inc., One Amgen Center Drive, Thousand Oaks, California, 91320, USA
- 2. Clinical Immunology, Amgen Inc., Thousand Oaks, California, 91320, USA
- 3. Comparative Biology and Safety Sciences, Amgen Inc., Thousand Oaks, California, 91320, USA